✦ The Future BetsNarrow moat
Eli Lilly (LLY) — the future bets
Lilly's futures come with p-values attached — a pill for the needle-averse, a triple agonist that ran the table, an Alzheimer's blood test, and a one-shot answer to untreatable heart risk.
Lilly's future bets are unusually legible, because pharmaceutical futures come with dates, doses and p-values attached. The current slate reads like a company attacking its own franchise before anyone else can — which is precisely the strategy.
Four are live. The oral era arrived on April 1, 2026, when the FDA approved Foundayo — orforglipron, the first GLP-1 pill that needs no food or water restrictions — priced from $149 a month for cash payers and shipped through LillyDirect within the week1. Behind it comes retatrutide, the triple agonist, sweeping its Phase 3 TRIUMPH program: average weight loss up to 71 pounds, osteoarthritis pain relief, trials two and three meeting every primary endpoint, with filings submitted in 20262. The third front is Alzheimer's, where Kisunla shows growing benefit over three years of treatment3 and Lilly's P-tau217 blood test threatens to replace the PET scan — a diagnostic that could multiply the treatable population. And the long shot is lepodisiran, an siRNA that cut lipoprotein(a) — the untreatable cardiac risk factor carried by a fifth of humanity — by 94% in Phase 2, now running a 17,300-patient outcomes trial that reads out toward 20294.
The pattern deserves naming: every bet either extends the incretin franchise (the pill, the triple agonist) or opens a market the size of one (Alzheimer's screening, cardiovascular prevention). The honest caveats are pharmaceutical gravity — Phase 3 sweeps do not guarantee pricing, access or persistence — and the fact that a ~$50 billion capacity build5 assumes demand keeps its promises. Watch Foundayo's launch curve against Novo's oral rival, the retatrutide approvals landing off the 2026 filings, and enrollment holding in the trials that turn screening into treatment.
Widening on dated milestones: Foundayo approved and shipping, retatrutide sweeping TRIUMPH into 2026 filings, Kisunla's three-year data landing, the blood test extending toward screening. Only the Lp(a) long shot waits — the rest of the slate converted promises into approvals and applications inside a year.
The bets exist to lower this number. Still rising in 2028 would mean the pipeline has not yet produced a second franchise.
- ReportedFoundayo (orforglipron) approved Apr 1, 2026 — $149/mo self-pay entry, LillyDirect from launch week.Eli Lilly — FDA approves Foundayo (orforglipron), the first GLP-1 pill for weight loss with no food/water/timing restrictions (Apr 1, 2026); ATTAIN Phase 3 program (4,500+ participants); ~12.4% average weight loss at the top dose; LillyDirect availability from Apr 6 — Apr 2026 · publ. Apr 1, 2026 · source ↗
- ReportedRetatrutide swept TRIUMPH: up to 71.2 lbs average loss; OA pain relief; 2026 filings.Eli Lilly — retatrutide Phase 3: average weight loss up to 71.2 lbs plus substantial osteoarthritis pain relief (TRIUMPH-4: 28.7% at 12mg, WOMAC pain −75.8%); TRIUMPH-1 (May 2026) the program's largest average loss — Dec 2025 – May 2026 · publ. 2025–2026 · source ↗
- ReportedKisunla showed growing benefit over three years of treatment.Eli Lilly — Kisunla (donanemab-azbt) showed growing benefit over three years of continued treatment in early symptomatic Alzheimer's disease — 2026 · publ. 2026 · source ↗
- ReportedLepodisiran cut Lp(a) ~94% in Phase 2; ACCLAIM runs 17,300 patients toward ~2029.ClinicalTrials.gov NCT06292013 — ACCLAIM-Lp(a): lepodisiran cardiovascular-outcomes trial, an estimated 17,300 adults with elevated Lp(a); Phase 2 ALPACA showed ~93.9% Lp(a) reduction; estimated completion ~2029 — Ongoing (to ~2029) · publ. 2026 status · source ↗
- ReportedThe ~$50B capacity build assumes demand keeps its promises.Lilly manufacturing commitments — tens of billions (~$50B announced) in new plants for incretin capacity — 2023-2026 · publ. 2023-2026 · source ↗